This is a table of type bigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.
bigram | frequency |
---|---|
type i | 4852 |
immune response | 2815 |
innate immune | 2493 |
immune responses | 2222 |
virus infection | 2101 |
i ifn | 2069 |
nk cells | 1932 |
respiratory syndrome | 1904 |
dendritic cells | 1720 |
infected cells | 1457 |
gene expression | 1446 |
immune system | 1423 |
influenza virus | 1323 |
i interferon | 1305 |
viral infection | 1243 |
acute respiratory | 1117 |
epithelial cells | 1117 |
viral replication | 1051 |
peripheral blood | 1048 |
virus replication | 1027 |
innate immunity | 1016 |
cell lines | 1004 |
viral infections | 1000 |
viral rna | 964 |
cell line | 935 |
severe acute | 896 |
flow cytometry | 854 |
cell responses | 810 |
antiviral activity | 796 |
bone marrow | 791 |
inflammatory cytokines | 787 |
syndrome coronavirus | 763 |
cd cd | 753 |
chronic hepatitis | 752 |
like receptor | 745 |
respiratory syncytial | 739 |
stranded rna | 732 |
syncytial virus | 721 |
cell death | 716 |
nk cell | 709 |
class i | 687 |
amino acid | 661 |
antiviral response | 656 |
porcine reproductive | 652 |
respiratory tract | 651 |
class ii | 650 |
lymph nodes | 640 |
natural killer | 639 |
i ifns | 626 |
significantly higher | 625 |
signaling pathway | 617 |
important role | 612 |
syndrome virus | 609 |
necrosis factor | 600 |
ifn signaling | 593 |
inflammatory response | 588 |
type iii | 579 |
ifn production | 579 |
ng ml | 578 |
mg kg | 568 |
adaptive immune | 563 |
mononuclear cells | 550 |
cell proliferation | 545 |
rna viruses | 544 |
mhc class | 538 |
cell types | 535 |
ifn response | 532 |
control group | 530 |
herpes simplex | 527 |
present study | 524 |
transcription factor | 510 |
regulatory factor | 508 |
immune cells | 506 |
cytokine production | 502 |
like receptors | 496 |
mrna expression | 486 |
specific cd | 484 |
cell activation | 484 |
simplex virus | 477 |
viral load | 470 |
high levels | 455 |
healthy controls | 454 |
nitric oxide | 453 |
results suggest | 452 |
growth factor | 450 |
protein kinase | 447 |
doc id | 445 |
cord uid | 445 |
infected mice | 436 |
multiple sclerosis | 435 |
hbv dna | 433 |
cell surface | 432 |
pg ml | 431 |
blood mononuclear | 430 |
type ii | 429 |
virus infections | 429 |
middle east | 422 |
interferon regulatory | 418 |
signaling pathways | 416 |
transcription factors | 416 |
nervous system | 415 |
mbl levels | 413 |
tumor necrosis | 412 |
mouse model | 409 |
monoclonal antibody | 407 |
endothelial cells | 407 |
cell culture | 406 |
east respiratory | 402 |
adaptive immunity | 402 |
ebola virus | 398 |
clinical trials | 385 |
results indicate | 380 |
host cell | 378 |
viral proteins | 377 |
antiviral responses | 375 |
pattern recognition | 375 |
nucleic acid | 374 |
west nile | 372 |
deficient mice | 369 |
cell response | 368 |
central nervous | 368 |
time points | 367 |
protein expression | 367 |
virus type | 361 |
cellular immune | 361 |
time pcr | 359 |
expression levels | 358 |
signal transduction | 358 |
cd cells | 355 |
ifn induction | 353 |
proinflammatory cytokines | 351 |
mg ml | 350 |
stimulated genes | 350 |
i interferons | 350 |
host defense | 339 |
nile virus | 337 |
data suggest | 335 |
significantly increased | 332 |
previously described | 331 |
fever virus | 330 |
poly i | 329 |
dependent manner | 328 |
inflammatory responses | 326 |
dengue virus | 325 |
hepatitis virus | 323 |
ex vivo | 322 |
hcv rna | 321 |
disease virus | 321 |
infected patients | 319 |
may also | 316 |
ns protein | 315 |
sendai virus | 314 |
blood samples | 312 |
disease severity | 312 |
th cells | 310 |
plasmacytoid dendritic | 309 |
wt mice | 308 |
sars coronavirus | 307 |
amino acids | 305 |
critical role | 302 |
monoclonal antibodies | 301 |
severe covid | 298 |
cd expression | 297 |
performed using | 297 |
inflammatory cytokine | 296 |
hepatocellular carcinoma | 296 |
animal models | 295 |
infectious diseases | 295 |
complement activation | 294 |
cell subsets | 293 |
recognition receptors | 293 |
nonstructural protein | 289 |
clinical trial | 289 |
cov infection | 288 |
interferon signaling | 284 |
cancer cell | 284 |
determine whether | 282 |
binding protein | 280 |
binding lectin | 280 |
host immune | 280 |
interferon production | 278 |
interferon response | 277 |
higher levels | 276 |
side effects | 275 |
innate antiviral | 274 |
iga protease | 273 |
increased levels | 272 |
cells may | 272 |
wild type | 271 |
respiratory viruses | 271 |
mrna levels | 269 |
mouse hepatitis | 268 |
cells infected | 267 |
alpha beta | 266 |
two groups | 264 |
previous studies | 264 |
patients receiving | 263 |
statistically significant | 263 |
antibody responses | 263 |
neutralizing antibodies | 262 |
hcv infection | 262 |
whole blood | 262 |
significantly reduced | 261 |
alveolar macrophages | 261 |
influenza viruses | 261 |
coronavirus infection | 260 |
host innate | 258 |
taken together | 256 |
mammalian cells | 256 |
nuclear translocation | 256 |
significant differences | 255 |
significantly lower | 255 |
clinical signs | 255 |
encephalitis virus | 254 |
total rna | 254 |
host cells | 252 |
antiviral signaling | 250 |
liver disease | 250 |
mice infected | 248 |
rna virus | 248 |
antiviral state | 248 |
protein synthesis | 246 |
iga antibody | 244 |
viral clearance | 243 |
vaccinia virus | 243 |
rv infection | 243 |
mg dl | 243 |
western blot | 243 |
target cells | 241 |
epithelial cell | 241 |
myeloid cells | 240 |
killer cells | 240 |
lung injury | 239 |
jak stat | 239 |
nucleic acids | 239 |
antiviral immunity | 238 |
described previously | 237 |
rna replication | 237 |
dendritic cell | 237 |
healthy individuals | 237 |
stem cell | 236 |
i signaling | 236 |
rsv infection | 234 |
immunodeficiency virus | 234 |
risk factors | 234 |
presenting cells | 234 |
stat signaling | 232 |
significant increase | 231 |
antigen presentation | 230 |
iii ifns | 230 |
mouth disease | 230 |
cell type | 229 |
lymph node | 229 |
beta interferon | 229 |
cell receptor | 228 |
significant difference | 227 |
antiviral effect | 225 |
like domain | 224 |
highly pathogenic | 224 |
liver transplantation | 224 |
results showed | 223 |
antiviral therapy | 223 |
stem cells | 223 |
blood donors | 222 |
cytokine storm | 222 |
recent studies | 222 |
well plates | 222 |
stimulated gene | 220 |
rheumatoid arthritis | 219 |
induced ifn | 217 |
activated macrophages | 216 |
cytokine responses | 216 |
increased expression | 216 |
genes involved | 215 |
interferon alpha | 215 |
influenza infection | 215 |
killer cell | 214 |
iu ml | 214 |
hela cells | 214 |
rift valley | 214 |
mediated antiviral | 213 |
specific antibodies | 213 |
immune evasion | 212 |
valley fever | 210 |
lower respiratory | 210 |
positive cells | 209 |
results demonstrate | 209 |
human cells | 208 |
iav infection | 208 |
western blotting | 208 |
virus ns | 207 |
iii ifn | 207 |
breast cancer | 207 |
copies ml | 206 |
human ifn | 205 |
binding site | 204 |
novel coronavirus | 204 |
respiratory distress | 203 |
may play | 203 |
endoplasmic reticulum | 203 |
vesicular stomatitis | 202 |
cell cycle | 201 |
tumour necrosis | 201 |
respiratory infections | 200 |
adverse events | 200 |
rna polymerase | 200 |
molecular mechanisms | 199 |
porcine epidemic | 199 |
diarrhea virus | 199 |
previously reported | 199 |
ifn responses | 199 |
i molecules | 198 |
cell function | 198 |
like protease | 198 |
antibody response | 198 |
bl mice | 197 |
autoimmune diseases | 197 |
airway epithelial | 196 |
immune signaling | 194 |
blood cells | 194 |
structural proteins | 194 |
disease progression | 193 |
airway inflammation | 193 |
stat pathway | 193 |
antiviral innate | 192 |
inhibitory effect | 192 |
host response | 192 |
cell cultures | 192 |
combination therapy | 192 |
low levels | 192 |
cell epitopes | 191 |
protective immunity | 190 |
ubiquitin ligase | 190 |
viral protein | 189 |
lateral flow | 189 |
mice immunized | 188 |
recombinant human | 188 |
stomatitis virus | 188 |
tumor cells | 187 |
antiviral activities | 187 |
prrsv infection | 187 |
retinoic acid | 186 |
protein levels | 184 |
lactic acid | 183 |
liver failure | 183 |
case report | 183 |
may contribute | 182 |
inducible gene | 182 |
tract infections | 182 |
protease activity | 181 |
alternatively activated | 181 |
pivotal role | 180 |
also found | 180 |
tumour cells | 179 |
hbv infection | 179 |
rhinovirus infection | 179 |
differentially expressed | 178 |
surface expression | 178 |
also observed | 178 |
human immunodeficiency | 178 |
inflammatory mediators | 178 |
adhesion molecules | 177 |
oral mucosa | 177 |
chronic inflammatory | 177 |
cancer cells | 177 |
th responses | 176 |
adaptor protein | 176 |
epidemic diarrhea | 176 |
mhc i | 176 |
nuclear factor | 175 |
immune cell | 175 |
pulmonary fibrosis | 175 |
room temperature | 175 |
major histocompatibility | 175 |
avian influenza | 174 |
severe disease | 173 |
luciferase reporter | 173 |
cell differentiation | 173 |
escherichia coli | 173 |
proliferating cells | 173 |
patients treated | 172 |
recent study | 172 |
acid bacteria | 172 |
cytosolic dna | 172 |
human collectins | 171 |
inflammatory cells | 171 |
septic shock | 171 |
crystal structure | 171 |
key role | 171 |
lectin pathway | 170 |
bacterial infections | 170 |
united states | 170 |
intracellular ifn | 169 |
critically ill | 169 |
liver cirrhosis | 169 |
reverse transcription | 169 |
antiviral effects | 168 |
rlr signaling | 167 |
ifn treatment | 167 |
clinical studies | 166 |
lung function | 166 |
antiviral immune | 166 |
distress syndrome | 166 |
apoptotic cells | 166 |
interferon induction | 166 |
stat phosphorylation | 165 |
body weight | 165 |
dc maturation | 164 |
lower levels | 164 |
vero cells | 163 |
mediated immune | 163 |
vascular endothelial | 162 |
two patients | 162 |
healthy donors | 161 |
increased risk | 161 |
negatively regulates | 161 |
type ifn | 161 |
hcv replication | 161 |
acute phase | 160 |
histocompatibility complex | 160 |
coronavirus disease | 160 |
dna vaccine | 159 |
healthy volunteers | 159 |
cell cytotoxicity | 159 |
may therefore | 159 |
induced apoptosis | 158 |
mean age | 158 |
activated protein | 157 |
data indicate | 157 |
increased susceptibility | 156 |
upper respiratory | 156 |
time point | 155 |
lupus erythematosus | 155 |
receptor signaling | 155 |
university hospital | 154 |
proinflammatory cytokine | 153 |
virus nonstructural | 153 |
systemic lupus | 153 |
major role | 153 |
intensive care | 153 |
one patient | 153 |
cell populations | 152 |
th th | 152 |
molecular patterns | 151 |
viral titers | 151 |
risk factor | 151 |
human interferon | 151 |
human lung | 151 |
neutralizing antibody | 151 |
phase i | 151 |
human blood | 151 |
analyzed using | 151 |
interferon gamma | 151 |
days post | 151 |
cytokine response | 151 |
respiratory viral | 151 |
also known | 151 |
serum levels | 150 |
closely related | 150 |
receptor expression | 150 |
viral genome | 150 |
spike protein | 150 |
may lead | 149 |
cells expressing | 149 |
findings suggest | 149 |
human peripheral | 149 |
culture supernatants | 148 |
clinical use | 148 |
vitro stimulation | 148 |
bovine serum | 147 |
cytokine levels | 147 |
white blood | 147 |
mediated signaling | 147 |
viral entry | 147 |
immune activation | 147 |
producing cells | 147 |
associated molecular | 146 |
persistent infection | 146 |
staphylococcus aureus | 146 |
transplant recipients | 146 |
treated mice | 145 |
statistical analysis | 145 |
surface markers | 145 |
negative feedback | 145 |
commercially available | 145 |
fold change | 145 |
binding assays | 145 |
monocytes macrophages | 145 |
chain reaction | 144 |
first line | 144 |
independent experiments | 144 |
nkt cells | 144 |
three times | 144 |
protective effect | 143 |
listeria monocytogenes | 143 |
mediated ifn | 143 |
mouse models | 143 |
two different | 142 |
proteome analysis | 142 |
mycobacterium tuberculosis | 141 |
life cycle | 141 |
host factors | 141 |
derived macrophages | 141 |
infectious virus | 141 |
infectious disease | 141 |
cell development | 141 |
following infection | 141 |
primary immunodeficiency | 141 |
graft survival | 140 |
ear skin | 140 |
crucial role | 140 |
weight loss | 140 |
combined immunodeficiency | 140 |
family members | 140 |
japanese encephalitis | 140 |
transgenic mice | 140 |
animal model | 140 |
single nucleotide | 140 |
tlr signaling | 140 |
control donors | 139 |
significantly decreased | 139 |
gut flora | 139 |
human rhinovirus | 139 |
peptide antigens | 139 |
ifn expression | 139 |
virus titers | 138 |
findings indicate | 138 |
specific immune | 138 |
public health | 138 |
cells showed | 138 |
polymerase chain | 138 |
autologous bacteria | 138 |
systematic review | 138 |
respiratory virus | 138 |
serine protease | 138 |
dna viruses | 138 |
irf activation | 138 |
specific antibody | 137 |
lactobacillus spp | 137 |
immune dysregulation | 137 |
ifn species | 137 |
humoural responses | 137 |
common cold | 137 |
cancer patients | 137 |
ms patients | 137 |
inflammatory diseases | 136 |
high mbl | 136 |
control animals | 136 |
effector cells | 136 |
corresponding hc | 136 |
structural protein | 136 |
mediated immunity | 136 |
mouse ifn | 135 |
tissue damage | 135 |
i expression | 135 |
tissue culture | 135 |
analysed using | 135 |
may help | 135 |
sequence homology | 135 |
pedv nsp | 135 |
lactobacillus acidophilus | 134 |
infection may | 133 |
human recombinant | 133 |
blot analysis | 133 |
patients infected | 133 |
intestinal epithelial | 133 |
induce ifn | 133 |
different time | 132 |
sentinel lymph | 132 |
related lipoproteins | 132 |
strand rna | 132 |
ill patients | 132 |
abstract case | 132 |
report text | 132 |
growth factors | 131 |
cytokine profile | 131 |
lung disease | 131 |
central role | 131 |
antigen presenting | 131 |
oxide synthase | 131 |
oligoadenylate synthetase | 131 |
recombinant ifn | 131 |
isg expression | 131 |
control groups | 130 |
interferon responses | 130 |
human coronavirus | 130 |
results show | 130 |
macrophage activation | 130 |
downstream signaling | 130 |
host antiviral | 130 |
survival rate | 130 |
ifn receptor | 130 |
oxidative stress | 130 |
gene products | 129 |
measles virus | 129 |
long term | 129 |
transforming growth | 129 |
rabies virus | 129 |
lung tissue | 129 |
adverse effects | 129 |
hla class | 128 |
endothelial growth | 128 |
patients received | 128 |
heat shock | 128 |
gene transcription | 128 |
several studies | 128 |
highly conserved | 127 |
microarray analysis | 127 |
cytokines il | 127 |
mhv infection | 127 |
human respiratory | 127 |
cohort study | 127 |
binding domain | 127 |
quantitative real | 127 |
studies will | 127 |
first time | 127 |
iii interferon | 127 |
reactive oxygen | 126 |
dna vaccination | 126 |
signaling cascade | 126 |
th response | 126 |
treated cells | 126 |
mast cells | 126 |
organ failure | 126 |
cell count | 126 |
fusion protein | 126 |
primary human | 125 |
large number | 125 |
binding proteins | 125 |
cd ra | 125 |
open reading | 125 |
antiviral defense | 125 |
cells via | 125 |
patients compared | 125 |
viral loads | 125 |
serum samples | 124 |
years old | 124 |
bd biosciences | 124 |
humoral immune | 124 |
signal transducer | 124 |
may provide | 124 |
borne encephalitis | 124 |
dna sensing | 123 |
previously shown | 123 |
sars patients | 123 |
allergic rhinitis | 123 |
liver biopsy | 123 |
preliminary results | 123 |
asthma exacerbations | 123 |
immune complexes | 122 |
colorectal cancer | 122 |
culture medium | 122 |
ifn regulatory | 122 |
alveolar epithelial | 122 |
type mice | 121 |
derived dendritic | 121 |
infected pigs | 121 |
rna helicase | 121 |
swine fever | 121 |
chronic hcv | 121 |
regression analysis | 120 |
bacterial infection | 120 |
infection induces | 120 |
gene therapy | 120 |
cell population | 120 |
clinical symptoms | 120 |
essential role | 120 |
transfected cells | 120 |
nipah virus | 120 |
cells treated | 119 |
rna interference | 119 |
antiviral drugs | 119 |
cell growth | 119 |
cell lysates | 119 |
high dose | 119 |
differential expression | 119 |
specific ifn | 119 |
different cell | 119 |
hemorrhagic fever | 118 |
human monocytes | 118 |
weaned pigs | 118 |
vitro studies | 118 |
stimulating factor | 118 |
authors declare | 118 |
positive patients | 118 |
plasma membrane | 118 |
well tolerated | 118 |
bronchoalveolar lavage | 117 |
murine coronavirus | 117 |
mortality rate | 117 |
acute viral | 117 |
protein inhibits | 117 |
significantly different | 117 |
mechanisms underlying | 117 |
flow cytometric | 117 |
fold higher | 117 |
infected animals | 117 |
igg antibodies | 117 |
mitochondrial antiviral | 117 |
treatment group | 117 |
weeks post | 116 |
plasma cells | 116 |
naturally occurring | 116 |
assay using | 116 |
produce ifn | 116 |
future studies | 116 |
i response | 116 |
significant reduction | 116 |
similar results | 116 |
bronchial asthma | 116 |
acute rejection | 115 |
rna synthesis | 115 |
molecular weight | 115 |
ifn system | 115 |
healthy blood | 115 |
antigen expression | 115 |
expression profiles | 114 |
serine proteases | 114 |
spinal cord | 114 |
pedv infection | 114 |
negative regulator | 114 |
th phenotype | 114 |
virus rna | 114 |
acid residues | 114 |
chronic liver | 113 |
mice compared | 113 |
clinical features | 113 |
ii cytokine | 113 |
controlled trial | 113 |
tumour cell | 113 |
results will | 113 |
acute lung | 113 |
acute infection | 112 |
cell entry | 112 |
proteasomal degradation | 112 |
empty vector | 112 |
even though | 112 |
nucleotide polymorphisms | 112 |
human monoclonal | 112 |
genomic rna | 111 |
cell signaling | 111 |
protease inhibitor | 111 |
complement activity | 111 |
using flow | 111 |
least one | 111 |
response towards | 111 |
protein level | 111 |
real time | 110 |
complement system | 110 |
parainfluenza virus | 110 |
analysis revealed | 110 |
investigated whether | 110 |
early stage | 110 |
post infection | 110 |
cytokine release | 109 |
cov nsp | 109 |
virus entry | 109 |
gel electrophoresis | 109 |
severe combined | 109 |
alpha interferon | 109 |
tlr ligands | 109 |
human cytomegalovirus | 108 |
investigate whether | 108 |
promoter activity | 108 |
type diabetes | 108 |
cytokine signaling | 108 |
many viruses | 108 |
ii expression | 108 |
lung epithelial | 108 |
currently investigating | 108 |
antiviral treatment | 108 |
yellow fever | 108 |
lymphocytic choriomeningitis | 108 |
cytokine secretion | 108 |
iga antibodies | 108 |
recently identified | 108 |
mice lacking | 108 |
statistical significance | 107 |
autoimmune encephalomyelitis | 107 |
patients showed | 107 |
cd bright | 107 |
significantly elevated | 107 |
persistently infected | 107 |
elevated levels | 107 |
sting pathway | 107 |
regulated genes | 106 |
expression level | 106 |
angelica tenuissima | 106 |
cellular immunity | 106 |
viral persistence | 106 |
stat activation | 106 |
interferon receptor | 106 |
pss patients | 106 |
previous study | 106 |
luciferase activity | 106 |
cellular proteins | 106 |
special emphasis | 106 |
cell transplantation | 106 |
mast cell | 106 |
ii ifn | 105 |
converting enzyme | 105 |
cells express | 105 |
remains unclear | 105 |
plasma levels | 105 |
liver injury | 105 |
cysteine protease | 105 |
mass spectrometry | 105 |
cells transfected | 104 |
recurrent infections | 104 |
i production | 104 |
specific cytotoxic | 104 |
memory cd | 104 |
immunized mice | 104 |
target bacteria | 104 |
barr virus | 104 |
clonally expanded | 104 |
wide range | 104 |
three different | 104 |
fold increase | 104 |
serum albumin | 104 |
oral carcinoma | 104 |
cell reactivity | 104 |
tenuissima nakai | 103 |
nucleocapsid protein | 103 |
signaling protein | 103 |
significantly associated | 103 |
cell activity | 103 |
melanoma differentiation | 103 |
dairy cows | 103 |
virus strain | 103 |
goat anti | 103 |
high level | 103 |
binding regions | 102 |
weak il | 102 |
inflammatory bowel | 102 |
virus particles | 102 |
chb patients | 102 |
high amounts | 102 |
ectopic gc | 102 |
negative regulators | 102 |
serum mbl | 102 |
normal mucosa | 102 |
mbl double | 102 |
mbl genotypes | 102 |
applied biosystems | 102 |
wnv infection | 102 |
feedback regulation | 102 |
clinical data | 102 |
liver transplant | 102 |
three groups | 102 |
negative regulation | 102 |
normal human | 101 |
high risk | 101 |
pegylated interferon | 101 |
associated protein | 101 |
secondary antibody | 101 |
knockout mice | 101 |
bioinformatics tools | 101 |
peritoneal macrophages | 101 |
protein microarrays | 101 |
vaccine development | 101 |
bronchial epithelial | 101 |
antibody microarrays | 101 |
fusion proteins | 101 |
reading frame | 101 |
inflammatory effects | 101 |
effector functions | 100 |
oxygen species | 100 |
ko mice | 100 |
pulmonary disease | 100 |
study showed | 100 |
negative bacteria | 100 |
studies using | 100 |
chronic viral | 100 |
cell counts | 100 |
plasmodium falciparum | 100 |
liver fibrosis | 100 |
cell membrane | 100 |
cytokine tumour | 100 |
global proteome | 100 |
buffered saline | 99 |
cytokine expression | 99 |
bacterial antigen | 99 |
transduced eph | 99 |
time rt | 99 |
gamma interferon | 99 |
sense rna | 99 |
mbl masp | 99 |
macrophage galactose | 99 |
recently reported | 99 |
database system | 99 |
bacteria lactobacillus | 99 |
ifitm proteins | 99 |
specific ctl | 99 |
specific igg | 99 |
hla supertypes | 99 |
mice treated | 99 |
induced activation | 99 |
zika virus | 98 |
analysis showed | 98 |
replication cycle | 98 |
hematopoietic stem | 98 |
mice showed | 98 |
liver function | 98 |
lysis buffer | 98 |
plaque assay | 98 |
experimental autoimmune | 98 |
endothelial cell | 97 |
autoimmune disease | 97 |
single amino | 97 |
cells using | 97 |
median age | 97 |
viral respiratory | 97 |
stress granule | 97 |
mechanical ventilation | 97 |
signaling proteins | 97 |
host responses | 97 |
suckling pigs | 97 |
ifn therapy | 96 |
ifn lambda | 96 |
uninfected cells | 96 |
terminal domain | 96 |
vaccine candidates | 96 |
binding sites | 96 |
cells within | 96 |
viral hepatitis | 96 |
lactobacillus rhamnosus | 96 |
potential role | 96 |
experimental infection | 96 |
family history | 96 |
coronavirus replication | 96 |
adaptor molecules | 96 |
reporter gene | 96 |
inhibits type | 95 |
vp protein | 95 |
clinical manifestations | 95 |
fetal bovine | 95 |
negative control | 95 |
prospective study | 94 |
bowel disease | 94 |
adhesion molecule | 94 |
tyrosine kinase | 94 |
nlrp inflammasome | 94 |
ctl activity | 94 |
five patients | 94 |
cellular response | 94 |
classical swine | 94 |
tract infection | 94 |
one study | 94 |
allergic airway | 94 |
prrsv nsp | 94 |
three independent | 94 |
hiv infection | 94 |
much higher | 94 |
another study | 94 |
antibodies specific | 94 |
treated group | 93 |
chronic obstructive | 93 |
structural basis | 93 |
renal function | 93 |
independent manner | 93 |
genes encoding | 93 |
live attenuated | 93 |
low dose | 93 |
among patients | 93 |
tumor growth | 93 |
dna damage | 93 |
rna degradation | 93 |
receptor binding | 92 |
progenitor cells | 92 |
virus clearance | 92 |
life technologies | 92 |
viral particles | 92 |
specific primers | 92 |
ebov infection | 92 |
gene i | 92 |
measured using | 92 |
interferon beta | 92 |
human disease | 92 |
cell mediated | 92 |
cell migration | 92 |
antiviral agents | 92 |
respiratory disease | 92 |
human dendritic | 92 |
poorly understood | 92 |
th cytokines | 91 |
core protein | 91 |
immune function | 91 |
type cytokines | 91 |
high affinity | 91 |
respiratory failure | 91 |
virus production | 91 |
pseudomonas aeruginosa | 91 |
major source | 91 |
inflammatory disease | 91 |
rhamnosus gg | 90 |
day post | 90 |
like protein | 90 |
studies showed | 90 |
protective role | 90 |
doublestranded rna | 90 |
data demonstrate | 90 |
large amounts | 90 |
will allow | 90 |
inducible nitric | 90 |
response rates | 90 |
inhibit ifn | 90 |
smooth muscle | 89 |
human papillomavirus | 89 |
obstructive pulmonary | 89 |
reverse transcriptase | 89 |
infected cell | 89 |
clinical course | 89 |
studies suggest | 89 |
multiple organ | 89 |
target genes | 88 |
first year | 88 |
dub activity | 88 |
positive control | 88 |
linked immunosorbent | 88 |
virus inhibits | 88 |
receptor complex | 88 |
cell lymphoma | 88 |
expressed genes | 88 |
possible role | 88 |
total number | 88 |
surface antigen | 88 |
biological activity | 88 |
acid substitution | 88 |
studies revealed | 88 |
idiopathic pulmonary | 88 |
mm tris | 87 |
irf phosphorylation | 87 |
per well | 87 |
determined using | 87 |
inhibitory effects | 87 |
lung pathology | 87 |
log copies | 87 |
serum hbv | 87 |
phase ii | 87 |
cancer treatment | 87 |
beneficial effects | 87 |
cytokine receptor | 86 |
fisher scientific | 86 |
apoptotic cell | 86 |
murine model | 86 |
marginal zone | 86 |
primary cells | 86 |
streptococcus pneumoniae | 86 |
expression pattern | 86 |
inflammasome activation | 86 |
mediated activation | 86 |
may cause | 86 |
copy number | 86 |
patients presented | 86 |
dna sensor | 86 |
reactive protein | 85 |
regulatory factors | 85 |
accessory proteins | 85 |
virological response | 85 |
firefly luciferase | 85 |
regional lymph | 85 |
host protein | 85 |
phosphorylated stat | 85 |
viral mrna | 85 |
cell viability | 85 |
virus vaccine | 85 |
cells play | 85 |
dependent rna | 85 |
cell numbers | 85 |
viral pathogenesis | 85 |
also showed | 85 |
data show | 84 |
lopinavir ritonavir | 84 |
induces apoptosis | 84 |
viral diseases | 84 |
clinical characteristics | 84 |
human airway | 84 |
induced type | 84 |
lactate dehydrogenase | 84 |
study group | 84 |
tlr expression | 84 |
inkt cells | 84 |
interferon lambda | 84 |
carcinoma cell | 84 |
nonstructural proteins | 84 |
patients without | 84 |
translation initiation | 84 |
better understanding | 84 |
treated patients | 84 |
kindly provided | 83 |
less pronounced | 83 |
control mice | 83 |
human cd | 83 |
thermo fisher | 83 |
encephalomyocarditis virus | 83 |
cancer immunotherapy | 83 |
otitis media | 83 |
human macrophages | 83 |
lung cancer | 83 |
low level | 83 |
nuclear localization | 83 |
expressing cells | 83 |
hek cells | 83 |
iii interferons | 83 |
survival rates | 83 |
immunol doi | 83 |
infected individuals | 82 |
cpg dna | 82 |
nuclear import | 82 |
human metapneumovirus | 82 |
respiratory symptoms | 82 |
viral evasion | 82 |
cell infiltration | 82 |
widely used | 82 |
protein content | 82 |
brain barrier | 82 |
mediated inhibition | 82 |
pathogen recognition | 82 |
cells decreased | 82 |
cell apoptosis | 82 |
severe influenza | 82 |
current study | 82 |
exome sequencing | 82 |
three patients | 82 |
induces type | 82 |
kinase pkr | 82 |
experimental rhinovirus | 82 |
gene induction | 82 |
stranded dna | 82 |
highly sensitive | 82 |
virus vp | 82 |
dna binding | 81 |
induced antiviral | 81 |
significant decrease | 81 |
subsequent development | 81 |
world health | 81 |
mediated degradation | 81 |
poor prognosis | 81 |
initiation factor | 81 |
lymphocyte subsets | 81 |
cytopathic effect | 80 |
subunit vaccine | 80 |
rhesus macaques | 80 |
target proteins | 80 |
viral antigens | 80 |
different species | 80 |
zoster virus | 80 |
may explain | 80 |
kidney transplant | 80 |
wound healing | 80 |
orally administered | 80 |
recombinant protein | 80 |
endou activity | 80 |
promoter region | 80 |
suppressor cells | 80 |
may represent | 80 |
also used | 80 |
san diego | 80 |
two distinct | 80 |
signaling molecules | 79 |
transmissible gastroenteritis | 79 |
final concentration | 79 |
derived peptides | 79 |
high viral | 79 |
convalescent plasma | 79 |
care unit | 79 |
transcriptional activation | 79 |
higher risk | 79 |
broad spectrum | 79 |
genomic dna | 79 |
ns proteins | 79 |
hospitalized patients | 79 |
different types | 79 |
also induces | 79 |
two major | 79 |
human nk | 79 |
bladder cancer | 79 |
spectrum antiviral | 79 |
th immune | 79 |
tnf production | 79 |
cell functions | 79 |
immune deficiency | 79 |
signaling cascades | 79 |
hcv core | 79 |
early stages | 79 |
virus infected | 79 |
cord blood | 78 |
serum il | 78 |
binding kinase | 78 |
induced cell | 78 |
virus strains | 78 |
mrna vaccines | 78 |
membrane protein | 78 |
protein production | 78 |
cystic fibrosis | 78 |
peptide epitopes | 78 |
viral antigen | 78 |
oligoadenylate synthetases | 78 |
maturation markers | 78 |
related molecules | 78 |
dependent innate | 78 |
commensal bacteria | 78 |
potential therapeutic | 78 |
infectious complications | 78 |
oral administration | 78 |
psoriatic skin | 78 |
showed increased | 78 |
increased production | 78 |
peptide ligands | 78 |
recent years | 78 |
antitumor activity | 78 |
blood monocytes | 78 |
activation state | 78 |
gene family | 78 |
genetic background | 78 |
virus titer | 78 |
also evaluated | 78 |
fully understood | 77 |
factor alpha | 77 |
associated coronavirus | 77 |
release assay | 77 |
complement components | 77 |
results indicated | 77 |
induced asthma | 77 |
drug resistance | 77 |
dna level | 77 |
supplementary material | 77 |
nude mice | 77 |
costimulatory molecule | 77 |
dna construct | 77 |
transcriptional activity | 77 |
isg conjugation | 77 |
lymphoid cells | 77 |
mediated protection | 77 |
splenic cd | 77 |
rna genome | 77 |
nsp protein | 77 |
cell immunity | 77 |
adoptive transfer | 77 |
chronic hbv | 77 |
within days | 77 |
high concentrations | 77 |
membrane fusion | 77 |
found among | 77 |
control cells | 77 |
viral dna | 76 |
pylori infection | 76 |
general hospital | 76 |
defense mechanisms | 76 |
sindbis virus | 76 |
peer review | 76 |
adult mice | 76 |
capsid protein | 76 |
terminal part | 76 |
antigen processing | 76 |
induced expression | 76 |
coronavirus nsp | 76 |
north american | 76 |
immune modulation | 76 |
clinical disease | 76 |
costimulatory molecules | 76 |
odds ratio | 76 |
well known | 76 |
may result | 76 |
cells compared | 76 |
also reported | 75 |
humoral immunity | 75 |
culture media | 75 |
dependent protein | 75 |
chikungunya virus | 75 |
interferon gene | 75 |
based vaccines | 75 |
highly significant | 75 |
therapeutic approach | 75 |
will also | 75 |
induced release | 75 |
mhc ii | 75 |
target cell | 75 |
leukemia virus | 75 |
molecular basis | 75 |
kg day | 75 |
tissue injury | 75 |
clinical outcome | 75 |
standard deviation | 75 |
ifn pathway | 75 |
regulatory role | 75 |
viral genomes | 75 |
increased significantly | 75 |
human gut | 75 |
immune status | 75 |
mouse igg | 75 |
stress granules | 75 |
largely unknown | 74 |
basic protein | 74 |
interstitial pneumonia | 74 |
important roles | 74 |
recognition molecules | 74 |
induced arthritis | 74 |
coronavirus papain | 74 |
first step | 74 |
antibody fragments | 74 |
renilla luciferase | 74 |
related genes | 74 |
lung inflammation | 74 |
activate nk | 74 |
cell layer | 74 |
may indicate | 74 |
peptides spanning | 74 |
nuclear export | 74 |
tlr agonist | 74 |
hong kong | 74 |
murine ifn | 74 |
toxoplasma gondii | 74 |
constitutively expressed | 74 |
full length | 74 |
logistic regression | 74 |
blood flow | 74 |
national institute | 74 |
immunomodulatory therapies | 74 |
fl fl | 74 |
increased viral | 74 |
multivariate analysis | 73 |
rantes expression | 73 |
complex class | 73 |
severe cases | 73 |
two types | 73 |
dust mite | 73 |
blood cell | 73 |
per group | 73 |
demyelinating disease | 73 |
mg bd | 73 |
cells derived | 73 |
cellular antiviral | 73 |
viral nucleic | 73 |
marrow transplantation | 73 |
human il | 73 |
vaccine design | 73 |
dna levels | 73 |
cell sorting | 73 |
virus induces | 73 |
single cell | 73 |
spleen cells | 73 |
peptide pools | 73 |
direct effect | 73 |
host proteins | 73 |
santa cruz | 73 |
immature dcs | 73 |
molecular markers | 73 |
may influence | 73 |
also demonstrated | 73 |
atopic dermatitis | 72 |
interferon stimulated | 72 |
rna recognition | 72 |
septic patients | 72 |
memory cells | 72 |
produce il | 72 |
eae induction | 72 |
inhibits ifn | 72 |
fluticasone propionate | 72 |
pcr analysis | 72 |
cultured cells | 72 |
factor receptor | 72 |
commonly used | 72 |
increasing evidence | 72 |
coli lps | 72 |
diabetes mellitus | 72 |
molecular mechanism | 72 |
ko animals | 72 |
mechanisms involved | 72 |
lymphoid tissues | 72 |
vascular complications | 72 |
mesenchymal stem | 71 |
sybr green | 71 |
significantly inhibited | 71 |
mortality rates | 71 |
large panel | 71 |
high degree | 71 |
postoperative infections | 71 |
reactive lymphocytes | 71 |
allergic asthma | 71 |
sars cov | 71 |
chronic infection | 71 |
contact sensitivity | 71 |
considered statistically | 71 |
elispot assay | 71 |
time course | 71 |
bacterial strains | 71 |
pulmonary tb | 71 |
type lectins | 71 |
antibody titers | 71 |
patients undergoing | 71 |
specific immunity | 71 |
protein microarray | 71 |
study demonstrated | 71 |
will address | 71 |
severe respiratory | 71 |
increasingly used | 71 |
also significantly | 71 |
lymphoid organs | 71 |
constitutive expression | 71 |
antiviral genes | 71 |
mxa protein | 71 |
proteins may | 71 |
protease domains | 71 |
tlr adaptor | 71 |
vaccine candidate | 71 |
lcm virus | 70 |
nadph oxidase | 70 |
randomized clinical | 70 |
chronic inflammation | 70 |
sfsv nss | 70 |
well established | 70 |
family member | 70 |
clinical outcomes | 70 |
signal peptide | 70 |
positive correlation | 70 |
final visit | 70 |
cyclic gmp | 70 |
mediated type | 70 |
viral spread | 70 |
previously demonstrated | 70 |
derived antigens | 70 |
ifn genes | 70 |
solid supports | 70 |
data provide | 70 |
therapeutic potential | 70 |
one hand | 70 |
shock protein | 70 |
results obtained | 70 |
mediated innate | 70 |
young children | 70 |
data presented | 70 |
also play | 70 |
infected cats | 70 |
respiratory illness | 70 |
tlr stimulation | 70 |
tnf receptor | 70 |
also shown | 70 |
pilot study | 70 |
therapeutic strategies | 70 |
gene transfer | 70 |
stimulated response | 69 |
standard operating | 69 |
quantitative rt | 69 |
viral rnas | 69 |
hcv genotype | 69 |
independent pathways | 69 |
specific cellular | 69 |
regression model | 69 |
zone macrophages | 69 |
choriomeningitis virus | 69 |
cytokine environment | 69 |
dm patients | 69 |
proteolytic cleavage | 69 |
clinical improvement | 69 |
chemokine expression | 69 |
provide new | 69 |
transplant patients | 69 |
focus score | 69 |
low tnf | 69 |
mt mt | 69 |
induced il | 69 |
transduced cell | 69 |
antibody production | 69 |
scale clinical | 69 |
myelin basic | 69 |
induce apoptosis | 69 |
antiviral action | 69 |
interferon genes | 69 |
malarial antigen | 69 |
infected macrophages | 69 |
gastric juice | 69 |
receptor antagonist | 69 |
bifidobacterium spp | 69 |
mbl gene | 69 |
cd foxp | 69 |
serum resistance | 69 |
kidney cells | 69 |
higher level | 69 |
associated serine | 69 |
production induced | 69 |
recall stimulation | 69 |
predisposing factor | 68 |
human mnsod | 68 |
clinical response | 68 |
ingested probiotics | 68 |
children living | 68 |
macrovascular complications | 68 |
aureus serotypes | 68 |
antiviral neutralization | 68 |
mediated opsonophagocytosis | 68 |
ics alone | 68 |
tcr vb | 68 |
hydrophobic interaction | 68 |
including ingested | 68 |
igg levels | 68 |
rna levels | 68 |
potentially immunogenic | 68 |
expression profiling | 68 |
lncbst bispr | 68 |
pylori igg | 68 |
monitor patients | 68 |
seroimmunological phenotype | 68 |
mt phenotype | 68 |
cytotoxicity increased | 68 |
cirrhotic patients | 68 |
currently trying | 68 |
induced rantes | 68 |
ra patients | 68 |
versus mg | 68 |
unstimulated cd | 68 |
normoalbuminuric group | 68 |
negatively regulate | 68 |
laboratory information | 68 |
double ko | 68 |
cd ro | 68 |
mbl ko | 68 |
cytolytic activity | 68 |
protected rats | 68 |
five putative | 68 |
associated gene | 68 |
igg caga | 68 |
persons working | 68 |
dietary vitamin | 68 |
rna binding | 68 |
normal colon | 68 |
microbial surfaces | 68 |
pneumoniae serotypes | 68 |
cell depletion | 68 |
analysis using | 68 |
hyperbaric exposure | 68 |
liver tissue | 68 |
mbp antibodies | 68 |
ige levels | 68 |
adaptor proteins | 68 |
colon mucosa | 68 |
normal range | 68 |
response element | 68 |
mbl pathway | 68 |
type interferon | 68 |
responsiveness ex | 68 |
health organization | 68 |
activate complement | 68 |
mt ratio | 68 |
sows fed | 68 |
noise threshold | 68 |
peptide mapping | 68 |
pressurized chamber | 68 |
inducible costimulator | 68 |
mt cells | 68 |
recently demonstrated | 68 |
ae sem | 67 |
predicted binding | 67 |
healthy control | 67 |
either ifn | 67 |
treg cells | 67 |
induced genes | 67 |
derived dcs | 67 |
skin lesions | 67 |
gastroenteritis virus | 67 |
cellular stress | 67 |
blood leucocytes | 67 |
laborious titrations | 67 |
higher incidence | 67 |
bioavailability varies | 67 |
well plate | 67 |
bat cells | 67 |
require laborious | 67 |
unique possibility | 67 |
novel markers | 67 |
red blood | 67 |
assays require | 67 |
hla supertype | 67 |
ifn biologicals | 67 |
micro flora | 67 |
enhanced ifn | 67 |
carried using | 67 |
hours post | 67 |
induced complement | 67 |
acute hepatitis | 67 |
experimental group | 67 |
may induce | 67 |
ifnar fl | 67 |
early phase | 67 |
membrane depolarization | 67 |
better reporter | 67 |
clinical practice | 67 |
innate response | 67 |
titrations making | 67 |
conjugated anti | 67 |
cytokine profiles | 67 |
colon cancer | 67 |
operating procedures | 67 |
sarcoid origin | 66 |
lung tissues | 66 |
macrophages elicited | 66 |
lavage fluid | 66 |
helicobacter pylori | 66 |
also induced | 66 |
cutaneous lymphocyteassociated | 66 |
sentinel nodes | 66 |
highthroughput global | 66 |
interaction chromatography | 66 |
mammalian cytokine | 66 |
intercellular contact | 66 |
novel allergen | 66 |
svegfr concentrations | 66 |
containing ic | 66 |
quantitative pcr | 66 |
invertebrate pattern | 66 |
nonsentinel lymph | 66 |
macrophage inflammatory | 66 |
activating enzyme | 66 |
acid sequence | 66 |
qbc peptides | 66 |
linked glycosylation | 66 |
allergen carriers | 66 |
viral pathogens | 66 |
venous blood | 66 |
specific nucleotidyl | 66 |
unstimulated cells | 66 |
recognition molecule | 66 |
different lab | 66 |
interferon antagonist | 66 |
microarrays will | 66 |
boost vaccinations | 66 |
tumour extract | 66 |
major cause | 66 |
obtain tumour | 66 |
times higher | 66 |
antitumour response | 66 |
affect nk | 66 |
plasma svegf | 66 |
soluble vascular | 66 |
generation anns | 66 |
svegfr release | 66 |
homing cutaneous | 66 |
rpe cells | 66 |
qbc experiment | 66 |
mbl concentration | 66 |
laboratory notebooks | 66 |
masp activity | 66 |
cells stimulated | 66 |
preoperative mbl | 66 |
janus kinase | 66 |
meld score | 66 |
bacterial stimulation | 66 |
variant tumour | 66 |
vascular permeability | 66 |
total igg | 66 |
rich data | 66 |
enriched ann | 66 |
ficolin ml | 66 |
acquired immunity | 66 |
lymphocyteassociated antigen | 66 |
mblassociated serine | 66 |
hyperimmunized mice | 66 |
hsv infection | 66 |
database solution | 66 |
evasion strategies | 66 |
ifnar signaling | 66 |
cell survival | 65 |
salivary glands | 65 |
expression analysis | 65 |
single dose | 65 |
magnetic beads | 65 |
ifit mice | 65 |
increased ifn | 65 |
direct antiviral | 65 |
also inhibit | 65 |
mammalian cell | 65 |
control subjects | 65 |
renal transplant | 65 |
mrna level | 65 |
hepg cells | 65 |
creative commons | 65 |
randomly selected | 65 |
using anti | 65 |
potent antiviral | 65 |
cells also | 65 |
hendra virus | 65 |
differences among | 65 |
mm nacl | 65 |
cells increased | 65 |
graft loss | 65 |
mrna translation | 65 |
also increased | 65 |
virologic response | 65 |
inflammatory monocytes | 65 |
mice deficient | 65 |
map kinase | 65 |
viral shedding | 65 |
important implications | 65 |
newcastle disease | 65 |
previous reports | 64 |
may allow | 64 |
tlr activation | 64 |
activity may | 64 |
cd th | 64 |
national institutes | 64 |
positive selection | 64 |
patient groups | 64 |
synthetic peptides | 64 |
effector memory | 64 |
protective immune | 64 |
directed mutagenesis | 64 |
receptor signalling | 64 |
antiviral drug | 64 |
th cell | 64 |
chemokine receptor | 64 |
units ml | 64 |
plasma samples | 64 |
disease activity | 64 |
virus challenge | 64 |
adult patients | 64 |
infectious bronchitis | 64 |
evidence suggests | 64 |
induced gene | 64 |
genes associated | 64 |
serum alt | 64 |
one year | 64 |
vast majority | 64 |
seven days | 64 |
data analysis | 64 |
immunological responses | 64 |
expression patterns | 64 |
cd dim | 63 |
months post | 63 |
may serve | 63 |
dose dependent | 63 |
influenza vaccine | 63 |
binding region | 63 |
increased cd | 63 |
host gene | 63 |
group i | 63 |
tlr agonists | 63 |
type immune | 63 |
saudi arabia | 63 |
vivo studies | 63 |
research institute | 63 |
also examined | 63 |
immune mechanisms | 63 |
granulomatous disease | 63 |
cell suspensions | 63 |
programmed cell | 63 |
plasmid dna | 63 |
respiratory infection | 63 |
cpg odn | 63 |
inducible protein | 63 |
cutting edge | 63 |
rna species | 63 |
pfu ml | 63 |
cell adhesion | 63 |
th cytokine | 63 |
last decade | 63 |
treated animals | 63 |
i activation | 63 |
interferon antiviral | 63 |
primary infection | 62 |
four patients | 62 |
low expression | 62 |
cov replication | 62 |
semliki forest | 62 |
huh cells | 62 |
therapeutic agents | 62 |
protein translation | 62 |
coronavirus infections | 62 |
observation period | 62 |
also expressed | 62 |
small interfering | 62 |
rabbit anti | 62 |
also detected | 62 |
secreting cells | 62 |
induce expression | 62 |
coding regions | 62 |
nucleotide sequence | 62 |
analysis reveals | 62 |
still unclear | 62 |
associated factor | 62 |
dependent pathway | 62 |
feline interferon | 62 |
mediated apoptosis | 62 |
survival time | 62 |
binding affinity | 62 |
different viruses | 62 |
medical microbiology | 62 |
million people | 62 |
cellular responses | 62 |
detection limit | 62 |
supplementary table | 62 |
mhc molecules | 62 |
linked ubiquitination | 62 |
high expression | 62 |
new insights | 62 |
may become | 62 |
i responses | 62 |
chronic rejection | 62 |
accessory protein | 62 |
old female | 61 |
animal studies | 61 |
patient survival | 61 |
ischemia reperfusion | 61 |
reperfusion injury | 61 |
molecular cloning | 61 |
sequence similarity | 61 |
protease domain | 61 |
considered significant | 61 |
might also | 61 |
fatty acids | 61 |
lesser extent | 61 |
way anova | 61 |
cytokine il | 61 |
using standard | 61 |
graft function | 61 |
human influenza | 61 |
model system | 61 |
immune systems | 61 |
expression profile | 61 |
dna virus | 61 |
cell recruitment | 61 |
rna sensing | 61 |
human leukocyte | 61 |
cardiovascular disease | 61 |
particularly important | 61 |
higher expression | 61 |
background aims | 61 |
including il | 61 |
data showed | 60 |
gene polymorphisms | 60 |
retrospective study | 60 |
diabetic patients | 60 |
washed twice | 60 |
antiviral functions | 60 |
medical center | 60 |
highly expressed | 60 |
interferon alfa | 60 |
induce type | 60 |
immune recognition | 60 |
secondary antibodies | 60 |
cytokine chemokine | 60 |
two independent | 60 |
cell carcinoma | 60 |
alternative pathway | 60 |
different groups | 60 |
signaling via | 60 |
high doses | 60 |
cells per | 60 |
responses following | 60 |
matrix protein | 60 |
viral encephalitis | 60 |
cytotoxic cd | 60 |
using different | 60 |
ii mhc | 60 |
i pathway | 60 |
sertoli cells | 60 |
i ii | 60 |
tgev pl | 60 |
old male | 60 |
neutrophil extracellular | 60 |
granule formation | 60 |
vascular endothelium | 60 |
using elisa | 60 |
sensitive detection | 60 |
molecules involved | 60 |
significant role | 60 |
herpes zoster | 59 |
physiological conditions | 59 |
remains unknown | 59 |
jev infection | 59 |
electron microscopy | 59 |
effector function | 59 |
results also | 59 |
bat species | 59 |
extracellular matrix | 59 |
common variable | 59 |
induced inflammatory | 59 |
studies show | 59 |
wildtype mice | 59 |
strongly inhibited | 59 |
different stages | 59 |
every weeks | 59 |
using human | 59 |
second messenger | 59 |
terminal region | 59 |
may account | 59 |
confocal microscopy | 59 |
inflammatory gene | 59 |
response elements | 59 |
factor irf | 59 |
genetic testing | 59 |
biologically active | 59 |
increased il | 59 |
porcine ifn | 59 |
pcr assay | 59 |
fmdv infection | 59 |
curative treatment | 59 |
induced protein | 59 |
pcr products | 59 |
blood cd | 59 |
carcinoma cells | 59 |
recently shown | 59 |
direct effects | 59 |
internal control | 59 |
increased mortality | 59 |
likely due | 59 |
antiviral protein | 59 |
draining lymph | 59 |
organ dysfunction | 59 |
interferon system | 58 |
blood pressure | 58 |
randomized controlled | 58 |
mice bearing | 58 |
human monocyte | 58 |
immunity via | 58 |
rna isolated | 58 |
endogenous ifn | 58 |
levels may | 58 |
ifn activation | 58 |
experiments showed | 58 |
showed significant | 58 |
lysine residues | 58 |
mg daily | 58 |
linked polyubiquitination | 58 |
following treatment | 58 |
bat irf | 58 |
copyright holder | 58 |
protein interactions | 58 |
fatty acid | 58 |
cells following | 58 |
mouse monoclonal | 58 |
exogenous ifn | 58 |
susceptible mice | 58 |
asthmatic patients | 58 |
human colon | 58 |
flow assays | 58 |
mouse strains | 58 |
cells producing | 58 |
human genome | 58 |
gene delivery | 58 |
plus tff | 58 |
unclear whether | 58 |
laboratory data | 57 |
complex formation | 57 |
specific cell | 57 |
hbeag negative | 57 |
severe infections | 57 |
nss protein | 57 |
recent advances | 57 |
rl mice | 57 |
immune sensing | 57 |
pandemic influenza | 57 |
biological activities | 57 |
effective treatment | 57 |
rotavirus infection | 57 |
host disease | 57 |
two doses | 57 |
virus disease | 57 |
liver damage | 57 |
protein interaction | 57 |
venezuelan equine | 57 |
cells might | 57 |
first days | 57 |
informed consent | 57 |
proliferative response | 57 |
per year | 57 |
host interactions | 57 |
two weeks | 57 |
gene product | 57 |
luciferase assay | 57 |
active site | 57 |
flow assay | 57 |
compared using | 57 |
mice per | 57 |
viral response | 57 |
forest virus | 57 |
chronic granulomatous | 57 |
ml min | 57 |
positive bacteria | 57 |
expression vector | 57 |
translational modification | 57 |
induced higher | 56 |
mediated inflammatory | 56 |
first years | 56 |
immune suppression | 56 |
including ifn | 56 |
ligase activity | 56 |
treatment groups | 56 |
spinal cords | 56 |
significant correlation | 56 |
inducible expression | 56 |
cellular functions | 56 |
diseases caused | 56 |
allograft rejection | 56 |
fl mice | 56 |
pegylated ifn | 56 |
expression plasmids | 56 |
treated rats | 56 |
least months | 56 |
like particles | 56 |
results may | 56 |
lower doses | 56 |
ifn antagonists | 56 |
mucosal sites | 56 |
studies involving | 56 |
hcc patients | 56 |
superoxide dismutase | 56 |
mv vac | 56 |
direct contact | 56 |
specific manner | 56 |
hbeag seroconversion | 56 |
facs analysis | 56 |
er stress | 56 |
viral titer | 56 |
vsv infection | 56 |
hcv ns | 56 |
therapeutic approaches | 56 |
hrv infection | 56 |
serum creatinine | 56 |
shock proteins | 56 |
provide evidence | 56 |
assay system | 56 |
significantly better | 56 |
virus glycoprotein | 55 |
caspase activation | 55 |
specific protease | 55 |
primary immunodeficiencies | 55 |
six patients | 55 |
various times | 55 |
systemic inflammatory | 55 |
ii molecules | 55 |
healthy subjects | 55 |
gene encoding | 55 |
liver diseases | 55 |
visceral leishmaniasis | 55 |
environmental factors | 55 |
four different | 55 |
produce type | 55 |
interferon therapy | 55 |
signal amplification | 55 |
blood cultures | 55 |
salivary gland | 55 |
beneficial effect | 55 |
viral disease | 55 |
mononuclear cell | 55 |
mononuclear phagocytes | 55 |
double stranded | 55 |
jhmv infection | 55 |
usp expression | 55 |
relatively low | 55 |
envelope protein | 55 |
ifn antagonism | 55 |
reporter assay | 55 |
immunological memory | 55 |
bovine viral | 55 |
embryonic fibroblasts | 55 |
hbeag positive | 55 |
alt levels | 55 |
innate lymphoid | 55 |
functional analysis | 55 |
cellular mechanisms | 55 |
porcine cells | 55 |
cleavage site | 55 |
adjuvant effect | 55 |
kidney transplantation | 55 |
host immunity | 54 |
triphosphate rna | 54 |
frhk cells | 54 |
animal care | 54 |
producing ifn | 54 |
seasonal influenza | 54 |
experimentally infected | 54 |
amp synthase | 54 |
steady state | 54 |
vitro experiments | 54 |
glial cells | 54 |
also indicated | 54 |
related proteins | 54 |
graft failure | 54 |
cytotoxic activity | 54 |
significantly enhanced | 54 |
stat stat | 54 |
autosomal recessive | 54 |
viral dsrna | 54 |
inducible genes | 54 |
age years | 54 |
exact test | 54 |
clinical study | 54 |
viral control | 54 |
cell subset | 54 |
positive feedback | 54 |
interfering rna | 54 |
human hepatocytes | 54 |
response rate | 54 |
molecular biology | 53 |
suppress ifn | 53 |
treatment response | 53 |
viral challenge | 53 |
cyclic di | 53 |
address whether | 53 |
protease inhibitors | 53 |
wide spectrum | 53 |
express il | 53 |
acutely infected | 53 |
abdominal pain | 53 |
findings may | 53 |
viral gene | 53 |
natural history | 53 |
cell lymphopenia | 53 |
small molecule | 53 |
alexa fluor | 53 |
induced lung | 53 |
currently available | 53 |
increased cell | 53 |
following i | 53 |
specific th | 53 |
different pathways | 53 |
least two | 53 |
mediated induction | 53 |
overall survival | 53 |
early life | 53 |
cells ul | 53 |
replacement therapy | 53 |
factors associated | 53 |
acid change | 53 |
human coronaviruses | 53 |
dependent signaling | 53 |
remain largely | 53 |
gene regulation | 53 |
surface receptors | 53 |
sequence information | 53 |
subcellular localization | 53 |
tumor cell | 53 |
nucleoside analogues | 53 |
cellular processes | 53 |
gastrointestinal tract | 53 |
better understand | 52 |
portal hypertension | 52 |
reduced viral | 52 |
ctl responses | 52 |
previous work | 52 |
binding motif | 52 |
tumor suppressor | 52 |
response induced | 52 |
capsid proteins | 52 |
inhibit viral | 52 |
intracellular pathogens | 52 |
lethal infection | 52 |
murine hepatitis | 52 |
prrsv replication | 52 |
nsp proteins | 52 |
specific igm | 52 |
also capable | 52 |
granted medrxiv | 52 |
developed using | 52 |
trypanosoma cruzi | 52 |
naturally infected | 52 |
isg induction | 52 |
also contribute | 52 |
induced inflammation | 52 |
last years | 52 |
small intestine | 52 |
cells respond | 52 |
renal failure | 52 |
observational study | 52 |
adefovir dipivoxil | 52 |
variable immunodeficiency | 52 |
severely impaired | 52 |
cell ifn | 52 |
study included | 52 |
oxide production | 52 |
kinase activity | 52 |
nkp high | 52 |
medical school | 52 |
renal disease | 52 |
equine encephalitis | 52 |
sting activation | 52 |
ifn antagonist | 52 |
proteins involved | 52 |
author funder | 52 |
hbv replication | 52 |
reduced il | 52 |
respiratory epithelial | 52 |
terminal amino | 51 |
mean time | 51 |
specific iga | 51 |
cells ml | 51 |
produce large | 51 |
stimulatory effect | 51 |
molecular mimicry | 51 |
genetic predisposition | 51 |
sensing pathway | 51 |
performed according | 51 |
hepatoma cells | 51 |
neutrophil recruitment | 51 |
normal individuals | 51 |
allow us | 51 |
two additional | 51 |
secreted ifn | 51 |
body mass | 51 |
like proteases | 51 |
genetic variation | 51 |
immunosorbent assay | 51 |
antibody levels | 51 |
activation via | 51 |
plasmon resonance | 51 |
inflammatory monocyte | 51 |
chronically infected | 51 |
version posted | 51 |
cellular rna | 51 |
activated cd | 51 |
hcv replicon | 51 |
cell immune | 51 |
flying fox | 51 |
transmembrane domain | 51 |
viral burden | 51 |
subsequent activation | 51 |
takes place | 51 |
crispr cas | 51 |
autosomal dominant | 51 |
surface plasmon | 51 |
bluetongue virus | 51 |
different mechanisms | 51 |
extracellular traps | 51 |
acute exacerbations | 51 |
high mortality | 51 |
initial phase | 51 |
ifn sav | 51 |
epidermal growth | 51 |
exact mechanisms | 51 |
cells well | 51 |
study also | 51 |
induced significant | 51 |
kupffer cells | 51 |
viral envelope | 51 |
may improve | 51 |
type lectin | 51 |
immune defense | 50 |
cell degranulation | 50 |
nsp inhibits | 50 |
studies suggested | 50 |
factor kappa | 50 |
vitro transcription | 50 |
days later | 50 |
tissue sections | 50 |
immune reaction | 50 |
may affect | 50 |
mannose receptor | 50 |
isotype switching | 50 |
containing protein | 50 |
evidence indicates | 50 |
vg vd | 50 |
fluorescent protein | 50 |
human populations | 50 |
marrow cells | 50 |
marker cd | 50 |
human ace | 50 |
tyrosine phosphorylation | 50 |
blood lymphocytes | 50 |
placebo group | 50 |
peripheral cd | 50 |
occurs via | 50 |
higher concentration | 50 |
thymidine incorporation | 50 |
mediated anti | 50 |
rhinovirus infections | 50 |
individual patients | 50 |
allergic reactions | 50 |
enzymatic activity | 50 |
human primary | 50 |
cell lysate | 50 |
urinary tract | 50 |
agarose gel | 50 |
tlr ligand | 50 |
study using | 50 |
injected i | 50 |
hepatic fibrosis | 49 |
chadox ncov | 49 |
induced signaling | 49 |
functional genomics | 49 |
human parainfluenza | 49 |
inhibitory receptor | 49 |
rights reserved | 49 |
phase iii | 49 |
liver cancer | 49 |
expression data | 49 |
blood sample | 49 |
host defenses | 49 |
responses may | 49 |
tumor microenvironment | 49 |
biological properties | 49 |
sample size | 49 |
interferon pathway | 49 |
feedback loop | 49 |
restriction factors | 49 |
master mix | 49 |
lymphoid tissue | 49 |
tcr repertoire | 49 |
mdck cells | 49 |
using lipofectamine | 49 |
viruses including | 49 |
induced interferon | 49 |
protein antigens | 49 |
like activity | 49 |
type infection | 49 |
gene silencing | 49 |
culture system | 49 |
vaccine formulation | 49 |
resistance mechanisms | 49 |
target gene | 49 |
front immunol | 49 |
human cell | 49 |
hours following | 49 |
novel therapeutic | 49 |
lcmv infection | 49 |
receptor agonist | 49 |
potent inhibitor | 49 |
type virus | 49 |
th day | 49 |
surfactant protein | 49 |
polyubiquitin chains | 49 |
showed significantly | 49 |
antibody titres | 49 |
ml ifn | 49 |
also involved | 49 |
similar effect | 49 |
study evaluated | 49 |
associated herpesvirus | 49 |
one case | 49 |
tripartite motif | 49 |
predictive value | 48 |
arginase activity | 48 |
following stimulation | 48 |
structurally related | 48 |
asthma control | 48 |
induced nf | 48 |
active molecules | 48 |
cellular protein | 48 |
normal levels | 48 |
negative patients | 48 |
enhanced type | 48 |
medium containing | 48 |
may reflect | 48 |
rna samples | 48 |
collagen type | 48 |
sle patients | 48 |
activated stat | 48 |
rna sensor | 48 |
da rats | 48 |
germinal centers | 48 |
laser scanning | 48 |
dna constructs | 48 |
gene factor | 48 |
bead array | 48 |
one day | 48 |
mg day | 48 |
macrophage colony | 48 |
negative controls | 48 |
containing fbs | 48 |
results suggested | 48 |
inflammatory skin | 48 |
protein induced | 48 |
probiotic strains | 48 |
transcriptional regulation | 48 |
rna expression | 48 |
pun rna | 48 |
clinical isolates | 48 |
will help | 48 |
almost exclusively | 48 |
ifn gene | 48 |
streptococcus pyogenes | 48 |
therapeutic targets | 48 |
important part | 48 |
retrospective cohort | 48 |
lymphocyte infiltration | 48 |
patients may | 48 |
endoribonuclease activity | 48 |
stress response | 48 |
viral genomic | 48 |
antiviral effector | 48 |
studies indicated | 48 |
inclusion criteria | 48 |
dramatically increased | 48 |
sequence analysis | 48 |
may potentially | 48 |
antiviral function | 48 |
adenosine deaminase | 47 |
least three | 47 |
twice daily | 47 |
rna sensors | 47 |
female mice | 47 |
tested positive | 47 |
lymphocyte proliferation | 47 |
direct interaction | 47 |
therapeutic efficacy | 47 |
mediated disease | 47 |
hcv patients | 47 |
immune escape | 47 |
signalling pathways | 47 |
median values | 47 |
effector mechanisms | 47 |
without affecting | 47 |
female patients | 47 |
even higher | 47 |
molecular mass | 47 |
innate responses | 47 |
immune pathways | 47 |
gamma production | 47 |
clinical efficacy | 47 |
inflammatory signaling | 47 |
year old | 47 |
ubiquitously expressed | 47 |
healthy adults | 47 |
tightly regulated | 47 |
restriction factor | 47 |
based vaccine | 47 |
culture supernatant | 47 |
sev cantell | 47 |
stage renal | 47 |
natural infection | 47 |
much less | 47 |
cell density | 47 |
malignant transformation | 47 |
thermo scientific | 47 |
severe clinical | 47 |
indicated time | 47 |
mitochondrial membrane | 47 |
antiviral protection | 47 |
pathogenic avian | 47 |
montanide isa | 47 |
reduced expression | 47 |
fruit bats | 47 |
mechanisms behind | 47 |
induced cd | 47 |
cell maturation | 47 |
signalling pathway | 47 |
studies indicate | 47 |
inflammatory processes | 47 |
patients suffering | 47 |
cytosolic rna | 47 |
rsv infections | 47 |
signal intensity | 47 |
infection model | 47 |
one hundred | 47 |
similar levels | 47 |
myeloid cell | 46 |
potential vaccine | 46 |
matched controls | 46 |
sustained virological | 46 |
confocal laser | 46 |
tlr pathways | 46 |
potential risk | 46 |
significantly correlated | 46 |
many studies | 46 |
liver cells | 46 |
relatively high | 46 |
inflammatory markers | 46 |
experimental groups | 46 |
primary function | 46 |
activates nf | 46 |
study period | 46 |
systemic inflammation | 46 |
cells positive | 46 |
causative agent | 46 |
calf serum | 46 |
exact role | 46 |
cell epitope | 46 |
vitro transcribed | 46 |
dnase i | 46 |
induce il | 46 |
play important | 46 |
much lower | 46 |
lower dose | 46 |
infection will | 46 |
tbk ikk | 46 |
treatment options | 46 |
sample preparation | 46 |
significant changes | 46 |
pathological conditions | 46 |
monocytic cell | 46 |
small number | 46 |
antiviral ifn | 46 |
mutant viruses | 46 |
cell frequencies | 46 |
later stages | 46 |
proliferation assays | 46 |
mg per | 46 |
human infection | 46 |
recombinant feline | 46 |
memory response | 46 |
readily detectable | 46 |
patients admitted | 46 |
ido ko | 46 |
virus load | 46 |
ctl response | 46 |
glycosylation site | 46 |
receptor activation | 46 |
liver biopsies | 46 |
cov spike | 46 |
intracellular signaling | 46 |